Endologix, a developer of minimally invasive treatments for aortic disorders, has presented the initial clinical results from the PEVAR Trial.
Endologix‘ PEVAR Trial is the first multicenter, prospective, randomized trial of totally percutaneous endovascular repair of abdominal aortic aneurysm and is being conducted at 20 centers in the US under an Investigational Device Exemption approved by the US Food and Drug Administration.
According to the study, among 33 patients enrolled in the Roll-In phase of the trial, technical success rates of 97% (access) and 100%(endovascular repair) have been achieved, with no major adverse events observed.
St Luke’s Episcopal Hospital participating investigator and presenter Zvonimir Krajcer said these initial outcomes in the PEVAR Trial roll-in phase are consistent with the published single center data, and have served to support initiation of the randomized phase of the trial.
"We are very pleased with the initial results, and look forward to completion of the randomized trial very soon," Krajcer said.